QuidelOrtho Corp
QuidelOrtho Corp develops and markets diagnostic testing products used to detect, monitor, and help manage disease across clinical and decentralized care settings. Its portfolio spans immunoassay, molecular testing, clinical chemistry, transfusion medicine, and point-of-care systems, with sales and operations across the United States and a global network serving more than 140 countries and territories.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueRapid diagnostic systems and assays used at or near the patient.
Central laboratory diagnostic instruments, reagents, and workflows.
Immunohematology and donor screening products for blood banks.
Molecular tests and related platforms for infectious disease and other uses.
Contract manufacturing and business collaborations outside core product sales.
Customers
QuidelOrtho sells to a mix of direct end users and distributors serving hospitals, clinical laboratories, physician offices, urgent care clinics, blood banks, donor centers, pharmacies, and other point-of-care settings. It also serves individual consumers through certain OTC products, while a meaningful portion of revenue comes through distributors that reach fragmented healthcare markets.
Buy and resell diagnostic products into multiple healthcare channels; important for reach in fragmented markets.
Purchase lab and molecular diagnostics for routine and specialized testing workflows.
Buy rapid point-of-care tests for fast clinical decisions at the site of care.
Use transfusion medicine and donor screening products to support blood safety and compatibility testing.
Buy selected consumer-facing tests for self-use or retail screening applications.
Strategy
QuidelOrtho’s strategy centers on broadening its diagnostic portfolio, supporting customers with direct service and distribution coverage, and using its installed commercial and manufacturing footprint to reach both developed and emerging markets. The company also emphasizes product validation, health-economic evidence, and service quality to reinforce adoption in point-of-care, laboratory, and transfusion medicine channels.
A wider test menu helps retain customers and cross-sell across care settings.
Channel mix must fit local market structure, especially in fragmented markets.
Diagnostic customers depend on consistent product availability and quality.
Geography
QuidelOrtho operates globally, with manufacturing facilities in the U.S., U.K., and China and commercial support across more than 140 countries and territories. Its reportable operating structure is organized around North America, EMEA, China, JPAC, and Latin America, with developed markets served more directly and emerging markets often served through distributors.
Risks
QuidelOrtho faces competition across multiple diagnostic categories, and demand can be concentrated in a small number of products, customers, and distributors. Its business is also exposed to supply chain disruption, regulatory and legal issues, and volatility in respiratory testing demand, while goodwill impairment and debt service add financial and accounting sensitivity.
- Customer and distributor concentrationImpact: HighLikelihood: Medium
A small number of distributors and direct customers account for a meaningful share of revenue.
Exposure: Loss of a key distributor or customer could reduce sales and market access.
- Respiratory testing demand volatilityImpact: HighLikelihood: Medium
A significant portion of revenue comes from respiratory products, including COVID-19 and flu tests.
Exposure - Supply chain and manufacturing disruptionImpact: HighLikelihood: Medium
The company relies on raw materials, components, and multi-country manufacturing.
Exposure - Goodwill impairmentImpact: High
Reporting unit fair values depend on revenue growth, margins, discount rates, and market multiples.
Exposure: Non-cash charges can be large when market capitalization or forecasts decline.
- Competitive pressureImpact: MediumLikelihood: Medium
The diagnostics market is highly competitive across point-of-care, lab, and molecular testing.
Exposure
Accounting
Judgemental itemsManagement uses discounted cash flow and market multiple methods with significant assumptions.
Impact: Can produce large non-cash charges when market value or outlook weakens.
A few products, customers and distributors drive a meaningful share of revenue.
Impact: Quarterly results can vary with respiratory demand and distributor ordering patterns.
Contract manufacturing and business collaborations are separate from core product sales.
Impact: Can affect mix, margins and comparability across periods.
The company recorded contract termination costs and legal accruals in recent periods.
Impact: These items can materially affect operating expense and earnings in a given year.
Similar listed companies
Publicly listed companies with a comparable business focus.
Qiagen N.V
QGEN · Biological Products, (No Diagnostic Substances)
Quest Diagnostics Incorporated
DGX · Services-Medical Laboratories
Quest Diagnostics is a U.S.-based clinical laboratory company that provides diagnostic testing, pathology, and related information services through a…
Quanterix Corp
QTRX · Laboratory Analytical Instruments
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples.
Insight Molecular Diagnostics Inc.
IMDX · In Vitro & In Vivo Diagnostic Substances
Revvity, Inc
RVTY · Laboratory Analytical Instruments
Revvity is a U.S.-based health science company that develops instruments, software, reagents, and services used across research, screening, diagnostics, and reproductive health workflows.
Longduoduo Co Ltd
LDDD · Services-Health Services
Longduoduo Co Ltd is a U.S.-listed company with operating subsidiaries in Inner Mongolia and Beijing that generates revenue from two main activities: direct…
Last updated: 24/09/2026